✦ LIBER ✦

Deferoxamine and coated charcoal hemoperfusion to remove aluminum in dialysis patients

✍ Scribed by McCarthy, James T; Milliner, Dawn S; Schmidt, David F; Schniepp, Brian J; Kurtz, Stephen B; Johnson, William J

Book ID: 109881140
Publisher: Nature Publishing Group
Year: 1988
Tongue: English
Weight: 519 KB
Volume: 34
Category: Article
ISSN: 0085-2538
DOI: 10.1038/ki.1988.253

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Accelerated Removal of Deferoxamine Mesy

Accelerated Removal of Deferoxamine Mesylate-Chelated Aluminum by Charcoal Hemoperfusion in Hemodialysis Patients

✍ Delmez, James; Weerts, Carol; Lewis-Finch, Jane; Windus, David; Slatopolsky, Edu 📂 Article 📅 1989 🏛 Elsevier Science 🌐 English ⚖ 538 KB

Deferoxamine Therapy Of Bone Aluminum Ac

Deferoxamine Therapy Of Bone Aluminum Accumulation In Renal Dialysis Patients

📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 265 KB

Deferoxamine Test and Bone Disease in Di

Deferoxamine Test and Bone Disease in Dialysis Patients With Mild Aluminum Accumulation

✍ de Vernejoul, Marie Christine; Marchais, Sylvain; London, Gerard; Bielakoff, Jos 📂 Article 📅 1989 🏛 Elsevier Science 🌐 English ⚖ 523 KB

Use of Deferoxamine in the Treatment of

Use of Deferoxamine in the Treatment of Aluminum Overload in Dialysis Patients

✍ Kenneth Abreo 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 821 KB

Deferoxamine-enhanced fecal losses of al

Deferoxamine-enhanced fecal losses of aluminum and iron in a patient undergoing continuous ambulatory peritoneal dialysis

✍ James T. McCarthy; Stephen B. Kurtz; Garry V. Mussman 📂 Article 📅 1987 🏛 Elsevier Science 🌐 English ⚖ 397 KB

Novel sorbents for removal of gadolinium

Novel sorbents for removal of gadolinium-based contrast agents in sorbent dialysis and hemoperfusion: preventive approaches to nephrogenic systemic fibrosis

✍ Wassana Yantasee; Glen E. Fryxell; George A. Porter; Kanda Pattamakomsan; Vichay 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 386 KB

## From the clinical editor: Chelated gadolinium (gd) contrast agents have been linked to a debilitating disease called nephrogenic systemic fibrosis (nsf) in patients with renal failure. free gd+(3) released from the contrast agents is believed to be the trigger for nsf. in this work, functionaliz